DUBLIN, April 1, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "HPAPIs and Cytotoxic Drugs Manufacturing Market (2nd Edition), 2016 - 2026" report to their offering.
The HPAPIs and Cytotoxic Drugs Manufacturing Market, 2016-2026 (2nd edition)' report provides an extensive study of the rapidly growing manufacturing market of HPAPIs and cytotoxic drugs. Due to their numerous advantages and widespread application in treatment of cancer and other disorders, HPAPIs and cytotoxics have emerged as one of the key focus areas of researchers across the globe.
With the rising demand for targeted therapies, high potency compounds such as high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have become the key focus of researchers and manufacturers worldwide. HPAPIs, which include cytotoxic APIs, are drug substances that are formulated to manufacture high potency drug products. Cytotoxic drugs are a category of highly potent drug products and, due to their increased utility in the treatment of cancer indications, have gained wide attention in recent years.
Some of the key benefits of these compounds include low dosage requirement and lower side effects. With over 25% of the total drugs worldwide being classified as highly potent, the HPAPI market is currently cited as one of the most important segments of pharmaceutical industry. The market is currently dominated by contract manufacturers.
Though some pharmaceutical companies have invested in building in-house capabilities, the capital intensive nature and specialized containment requirements make the role of contract manufacturers crucial. SAFC, Lonza and Evonik are amongst the pioneers in the field of manufacturing highly potent compounds. In addition, new entrants such as Labochim, Medichem, OPKO Health, Project Pharmaceutics, Regis Technologies, ScinoPharm and Wuxi Pharma have also recently sprung up.
The growing number of investments and partnerships in this field are evident of the current market intensity. Majority of the investments in recent years have been expansion programs highlighting that manufacturers are keen to expand their existing production facilities to meet the growing demand. Looking at the ongoing focus, we certainly believe that stakeholders will continue to invest in this area. The current market landscape will gradually evolve as manufacturers look to gain competitive advantage in the near future.
- Oncology is the key driver behind the growth of HPAPIs and cytotoxic drugs. Around 60% of the HPAPIs are being developed for the treatment of cancer. The trend is likely to continue and the anti-cancer market will sustain the growth of HPAPIs and cytotoxics in the future. - CMOs are the key stakeholders in the market as a good proportion of HPAPI / cytotoxics manufacturing is currently outsourced due to stringent manufacturing protocols and safety requirements. During our research, we identified 96 CMOs (with over 130 production facilities worldwide) that are focused in this area; approximately 40% of these facilities are dedicated to manufacturing of both HPAPIs and cytotoxic drugs. - The market is highly fragmented; companies such as Capsugel, Idifarma, Labochim, Medichem, OPKO Health, ScinoPharm, WuXi PharmaTech are some of the new entrants in this market that have recently expanded their service portfolio. Having said this, established pharma companies such as Roche, Merck, GSK, BMS and Boehringer Ingelheim have also established in-house capabilities. - Over 15% CMOs have established one-stop-shop model to provide manufacturing services for both HPAPI and finished cytotoxic drugs. Examples include AbbVie, AMRI, Baxter BioPharma Solutions, CordenPharma and Fareva. - North America and Europe are the predominant regions where HPAPI and cytotoxic drugs production facilities are located. The US accounts for around 23% of the total HPAPI production facilities followed by Italy (13%) and Switzerland (11%). In the case of cytotoxic drugs, 30% of production facilities are located in the US; this is followed by Germany (14%) and the UK (10%). Companies have also moved their focus to developing countries such as China and India in order to take advantage of relatively lower costs. - Several collaborations have been recently inked between stakeholders with an aim to combine their manufacturing expertise. Of the 50 partnerships we studied during our research, an overwhelming proportion were acquisitions (55%) and manufacturing collaborations (38%). - Catering to the wider demand, several CMOs have regularly engaged in investment programs to expand their production set ups. Since 2006, there have been more than 100 investments to add new facilities and / or to expand existing capacities; SAFC has led this activity followed by Novasep, Aesica Pharmaceuticals, CARBOGEN AMCIS, Lonza, Piramal, Helsinn and Baxter BioPharma Solutions. - Overall, the HPAPI and cytotoxic drugs market holds enormous potential for the contract manufacturers. We anticipate this opportunity for the CMOs to grow at an annualized rate of -10% over the next ten years. North American and Western European CMOs will continue to dominate with a share of over 70% in the overall market. Developing countries, such as India and China, are likely to emerge with a share of around 13% by 2026.
- AAIPharma Services Corp. - AB SCIEX - AbbVie - ACES Pharma - ADC Biotechnology - Aenova Group - Aesica Pharmaceuticals - Affinity Lifesciences - Agno Pharma - Ajinomoto Omnichem - Alkermes Contract Pharma Services - ALMAC Group - Alphora Research - Amatsigroup - AMPAC Fine Chemicals - AMRI - Aptuit - Arch Pharmalabs - Ash Stevens - Aspen Holdings - Asymchem Laboratories - AVANTHERA - Avecia - AzayaTherapeutics - Bachem - Banner Pharmacaps - Baxter BioPharma Solutions - Bayer - Bend Research - BioAgilytix Labs - BioOutsource - Biopharma Technology - Biotechnique - Biotest - BioVectra - Boehringer Ingelheim - Bristol Myers Squibb - Bryllan - BSP Pharmaceuticals - Cadila Healthcare - Cambrex - Cambridge Major Laboratories - Capsugel - CARBOGEN AMCIS - Catalent - Cedarburg Pharmaceuticals - Celldex Therapeutics - Celon Labs - Cerbios - ChemCon - ChemPartner - ChemSun Pharmaceutical - CMC Biologics - Coland Holdings - Coldstream Laboratories - Concortis Biosystems - CordenPharma - Creapharm Parenterals - Creative Biolabs - Cytovance Biologics - Dalton Pharma Services - Dishman Group - Dorizoe LifeSciences - Dottikon Exclusive Synthesis - Dr. Reddy's Laboratories - DSM Pharmaceuticals - EaglePicher Pharmaceutical Services - EirGen Pharma - EirGenix - Eisai - Eli Lilly - EMD Serono - Encap Drug Delivery - Eucodis Bioscience - Evonik - Excella GmbH - Fareva - Farmabios - Ferro Pfanstiehl - FineTech Pharmaceuticals - Foresee Pharmaceuticals - Formex - Formosa Laboratories - Fresenius Kabi - FUJIFILM Diosynth Biotechnologies - Gadea Pharmaceutical Group - Genentech - GlaxoSmithKline - Goodwin Biotechnology - GP Pharm - Granules - Haupt Pharma - Helsinn - Heraeus Deutschland GmbH & Co. KG (Chemicals Division of Heraeus Group) - Heraeus Precious Metals - Hikal - Hikma Pharmaceutical - Hospira - Holodiag - Hovione - iBIOSOURCE - Icrom - Idifarma - IDT Australia - ImmunoGen - Immunomedics - Indena - Infa Group - InSphero - Intas Pharmaceuticals - Intellect Neurosciences - IRIX Pharmaceuticals (acquired by Patheon) - Johnson & Johnson - Johnson Matthey Pharma Services - Kemwell - KKR & Co. - Kyongbo Pharmaceutical Co. Ltd - Labochim SpA - Lipocine - Lonza - Matrix Laboratories - Mayne Pharmaceuticals - Medichem - MedImmune - Merck Serono - Mersana Therapeutics - Metrics - Micron Technologies - Millennium Pharmaceuticals - MI-mAbs - Minafen - Natco Pharma - NerPharMa - Nerviano Medical Sciences - Neuland Laboratories - NextPharma Technologies - Nicholas Laboratories - Normon - Novartis - Novasep - Nycomed Amersham - Oasmia Pharmaceutical - Olon S.p.A. - Omni Chem - One2One (Hospira) - OPKO Health - Organichem - OsoBio - Pacific GMP - Patheon - Penn Pharma - Pfanstiehl - Pfizer CentreSource - Pharmascience - Pharmatek - Pierre Fabre Medicament Production - Piramal - Polymun Scientific - Polytherics - Powder Systems Limited - Prasfarma - Priaxon - Procos - Progenics Pharmaceuticals - ProJect Pharmaceutics - QPS Holdings - QS Pharma - Quanta BioDesign - Ranbaxy Laboratories - Redwood Biosciences - Regis Technologies - Roche - Rottendorf Pharma GmbH - Sigma Aldrich Fine Chemicals - Sandoz - Sanofi Aventis - ScinoPharm - SCM Pharma - Seattle Genetics - Serina Therapeutics - Siegfried - Spirogen - Stason Pharmaceuticals - Sumitra Pharmaceuticals - Sun European Partners - Sundia Meditech - Symbiosis Pharmaceutical Services - Syntagon - Syn-the-All Pharmaceutical Co. Ltd. (STA) - Synthon Biopharmaceuticals - TAPI - Tetrionics - The Chemistry Research Solution - Transporin - TUBE Pharma - Uman Pharma - UPM Pharmaceuticals - Vianex S.A. - Vion Pharmaceuticals - VUAB Pharma (acquired Brno plant in 2010) - VxP Pharmaceuticals - Waters - Wuxi Pharma
For more information visit http://www.researchandmarkets.com/research/sp9k7h/hpapis_and
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hpapis-and-cytotoxic-drugs-manufacturing-market-2026---research-and-markets-300244705.html
SOURCE Research and Markets